Review article: therapeutic bile acids and the risks for hepatotoxicity

Alimentary Pharmacology and Therapeutics

Volumn 47, Issue 12, 2018, Pages 1623-1638

  Ashby, K ^a   Navarro Almario, E E ^b   Tong, W ^a   Borlak, J ^c   Mehta, R ^b   Chen, M ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILE SALT EXPORT PUMP; BILIRUBIN; CCAAT ENHANCER BINDING PROTEIN; CHEMOKINE; CHENODEOXYCHOLIC ACID; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLIC ACID; CYTOKINE; DEATH RECEPTOR; DEOXYCHOLIC ACID; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE REGULATED PROTEIN 78; GLYCOCHENODEOXYCHOLIC ACID; GLYCOCHOLIC ACID; LITHOCHOLIC ACID; MULTIDRUG RESISTANCE PROTEIN 3; NORURSODEOXYCHOLIC ACID; OBETICHOLIC ACID; PLACEBO; REACTIVE OXYGEN METABOLITE; TAUROCHOLIC ACID; TAURODEOXYCHOLIC ACID; TAUROURSODEOXYCHOLIC ACID; TOLL LIKE RECEPTOR 9; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATP SYNTHESIS; BILE ACID BLOOD LEVEL; BILE ACID HOMOEOSTASIS; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BILE DUCT DISEASE; BILIARY CIRRHOSIS; BILIRUBIN BLOOD LEVEL; CEREBROTENDINOUS XANTHOMATOSIS; CHEMICAL COMPOSITION; CHEMICAL STRUCTURE; CHOLESTASIS; CHRONIC LIVER DISEASE; CONJUGATION; CYTOKINE RELEASE; DEATH RECEPTOR SIGNALING PATHWAY; DISEASE EXACERBATION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DISORDERS OF PEROXISOMAL FUNCTIONS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; ENDOPLASMIC RETICULUM STRESS; ENTEROHEPATIC CIRCULATION; ENZYME DEFECT; FATTY LIVER; GALLSTONE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS; HOMEOSTASIS; HUMAN; HYDROPHOBICITY; HYPERTRANSAMINASEMIA; INFLAMMATION; INNATE IMMUNITY; INTERNATIONAL NORMALIZED RATIO; LIPID TRANSPORT; LIVER CELL DAMAGE; LIVER FAILURE; LIVER FIBROSIS; LIVER INJURY; LIVER TOXICITY; MITOCHONDRIAL RESPIRATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE METABOLISM; OBSTRUCTIVE JAUNDICE; OFF LABEL DRUG USE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE ENZYME DEFECT; SPECIES DIFFERENCE; SYSTEMATIC REVIEW; ANIMAL; LIVER; METABOLISM; PATHOLOGY; TOXIC HEPATITIS;

ANIMALS; BILE ACIDS AND SALTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHENODEOXYCHOLIC ACID; CHOLESTASIS; HUMANS; LIVER;

EID: 85046022232     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14678     Document Type: Review

References (116)

1. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137-174.
2. Mekhjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J Clin Invest. 1971;50:1569.
3. Halilbasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol. 2013;58:155-168.
4. Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res. 2009;50:2340-2357.
5. Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med. 1999;159:2647-2658.
6. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362-1365.
7. Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci. 2008;65:2461-2483.
8. Schaap FG, Trauner M, Jansen PLM. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2014;11:55-67.
9. Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology. 2017;65:350-362.
10. Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 2014;66:948-983.
11. Nie B, Park HM, Kazantzis M, et al. Specific bile acids inhibit hepatic fatty acid uptake in mice. Hepatology. 2012;56:1300-1310.
12. Trauner M, Fuchs CD, Halilbasic E, Paumgartner G. New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Hepatology. 2017;65:1393-1404.
13. Ferrebee CB, Dawson PA. Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids. Acta Pharmaceutica Sinica B. 2015;5:129-134.
14. Chiang JY. Bile acids: regulation of synthesis. J Lipid Res. 2009;50:1955-1966.
15. Li M, Cai S-Y, Boyer JL. Mechanisms of bile acid mediated inflammation in the liver. Mol Aspects Med. 2017;56:45-53.
16. Kong B, Wang L, Chiang JY, Zhang Y, Klaassen CD, Guo GL. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology. 2012;56:1034-1043.
17. Cai S-Y, Xiong L, Wray CG, Ballatori N, Boyer JL. The farnesoid X receptor FXRα/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. Am J Physiol Regul Integr Comp Physiol. 2007;293:R1400-R1409.
18. Huber RM, Murphy K, Miao B, et al. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene. 2002;290:35-43.
19. Hwang ST, Urizar NL, Moore DD, Henning SJ. Bile acids regulate the ontogenic expression of ileal bile acid binding protein in the rat via the farnesoid X receptor. Gastroenterology. 2002;122:1483-1492.
20. Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology. 2009;49:1228-1235.
21. Hoeke MO, Heegsma J, Hoekstra M, Moshage H, Faber KN. Human FXR regulates SHP expression through direct binding to an LRH-1 binding site, independent of an IR-1 and LRH-1. PLoS ONE. 2014;9:e88011.
22. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol. 2014;30:332.
23. Barrett KE, Boitano S, Barman SM, Brooks HL. Chapter 28. Transport & Metabolic Functions of the Liver. In: Barrett KE, Boitano S, Barman SM, Brooks HL, eds. Ganong's Review of Medical Physiology. Vol 24. New York, NY: The McGraw-Hill Companies; 2012:509-518.
24. von Hardenberg S, Gnewuch C, Schmitz G, Borlak J. ApoE is a major determinant of hepatic bile acid homeostasis in mice. J Nutr Biochem. 2018;52:82-91.
25. Aldini R, Roda A, Festi D, et al. Bile acid malabsorption and bile acid diarrhea in intestinal resection. Dig Dis Sci. 1982;27:495-502.
26. Heuman DM. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res. 1989;30:719-730.
27. Perez MJ, Briz O. Bile-acid-induced cell injury and protection. World J Gastroenterol. 2009;15:1677.
28. Danzinger RG, Hofmann AF, Schoenfield LJ, Thistle JL. Dissolution of cholesterol gallstones by chenodeoxycholic acid. N Engl J Med. 1972;286:1-8.
29. Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med. 2007;357:1524-1529.
30. Kardorff R, Melter M, Rodeck B, Brodehl J. Long-term ursodeoxycholic acid treatment of cholestatic liver diseases in childhood–clinical and biochemical effects. Klin Padiatr. 1995;208:118-122.
31. Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology. 2011;53:1377-1387.
32. Bjornsson ES, Jonasson JG. Drug-induced cholestasis. Clin Liver Dis. 2013;17:191-209.
33. Schoenfield LJ, Lachin JM, Baum RA, et al. Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study: a controlled trial of efficacy and safety. Ann Intern Med. 1981;95:257-282.
34. Thistle JL, Hofmann AF. Efficacy and specificity of chenodeoxycholic acid therapy for dissolving gallstones. N Engl J Med. 1973;289:655-659.
35. Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med. 1984;311:1649-1652.
36. Roda E, Bazzoli F, Labate AMM, et al. Ursodeoxycholic acid vs. chenodeoxycholic acid as cholesterol gallstone-dissolving agents: A comparative randomized study. Hepatology. 1982;2:804-810.
37. Rubin RA, Kowalski TE, Khandelwal M, Malet PF. Ursodiol for hepatobiliary disorders. Ann Intern Med. 1994;121:207-218.
38. Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology. 1999;117:918-925.
39. Poupon RE, Balkau B, Eschwège E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 1991;324:1548-1554.
40. Leuschner U. Ursodeoxycholic acid therapy in primary biliary cirrhosis. Scand J Gastroenterol. 1994;29:40-46.
41. Ursodiol. Drugs.com. https://www.drugs.com/pro/ursodiol.html. Accessed August 2016.
42. URSO. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a061bb07-a85d-4b08-877f-ce02156f0de7. Accessed August 2016.
43. Li Z, Zhang M, Liu C, et al. Development of Liposome containing sodium deoxycholate to enhance oral bioavailability of itraconazole. Asian J Pharm Sci. 2016;12:157-164.
44. Ascher B, Hoffmann K, Walker P, Lippert S, Wollina U, Havlickova B. Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study. J Eur Acad Dermatol Venereol. 2014;28:1707-1715.
45. Chamilos G, Luna M, Lewis RE, Chemaly R, Raad II, Kontoyiannis DP. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. Clin Ther. 2007;29:1980-1986.
46. Obeticholic acid. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdfbe0cd-eb15-45a1-ac17-531bcda21aec. Accessed August 2016.
47. Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631-643.
48. Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis (NUC-3). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01755507?term=NCT01755507&rank=1. Accessed August 2016.
49. Gilat T, Somjen G, Mazur Y, et al. Fatty acid bile acid conjugates (FABACs)—new molecules for the prevention of cholesterol crystallisation in bile. Gut. 2001;48:75-79.
50. Hofmann AF. Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab Rev. 2004;36:703-722.
51. Yang K, Pfeifer ND, Köck K, Brouwer KL. Species differences in hepatobiliary disposition of taurocholic acid in human and rat sandwich-cultured hepatocytes: implications for drug-induced liver injury. J Pharmacol Exp Ther. 2015;353:415-423.
52. Javitt NB, Emerman S. Effect of sodium taurolithocholate on bile flow and bile acid excretion. J Clin Invest. 1968;47:1002.
53. Fischer C, Cooper N, Rothschild M, Mosbach E. Effect of dietary chenodeoxycholic acid and lithocholic acid in the rabbit. Dig Dis Sci. 1974;19:877-886.
54. Delzenne NM, Calderon PB, Taper H, Roberfroid M. Comparative hepatotoxicity of cholic acid, deoxycholic acid and lithocholic acid in the rat: in vivo and in vitro studies. Toxicol Lett. 1992;61:291-304.
55. Palmer A, Heywood R. Pathological changes in the rhesus fetus associated with the oral administration of chenodeoxycholic acid. Toxicology. 1974;2:239-246.
56. Dyrszka H, Salen G, Zaki F, Chen T, Mosbach E. Hepatic toxicity in the rhesus monkey treated with chenodeoxycholic acid for 6 months: biochemical and ultrastructural studies. Gastroenterology. 1976;70:93.
57. Song P, Zhang Y, Klaassen CD. Dose-response of five bile acids on serum and liver bile Acid concentrations and hepatotoxicty in mice. Toxicol Sci. 2011;123:359-367.
58. Hofmann AF, Mosbach EH, Sweeley CC. Bile acid composition of bile from germ-free rabbits. Biochim Biophys Acta. 1969;176:204-207.
59. Duanmu Z, Locke D, Smigelski J, et al. Effects of dexamethasone on aryl (SULT1A1)-and hydroxysteroid (SULT2A1)-sulfotransferase gene expression in primary cultured human hepatocytes. Drug Metab Dispos. 2002;30:997-1004.
60. Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci. 2001;98:3369-3374.
61. Makino I, Hashimoto H, Shinozaki K, Yoshino K, Nakagawa S. Sulfated and nonsulfated bile acids in urine, serum, and bile of patients with hepatobiliary diseases. Gastroenterology. 1975;68:545-553.
62. Bathena SPR, Thakare R, Gautam N, et al. Urinary bile acids as biomarkers for liver diseases II. Signature profiles in patients. Toxicol Sci. 2014;143:308-318.
63. Schwenk M, Hofmann A, Carlson G, Carter J, Coulston F, Greim H. Bile acid conjugation in the chimpanzee: effective sulfation of lithocholic acid. Arch Toxicol. 1978;40:109-118.
64. Huang J, Bathena SPR, Csanaky IL, Alnouti Y. Simultaneous characterization of bile acids and their sulfate metabolites in mouse liver, plasma, bile, and urine using LC–MS/MS. J Pharm Biomed Anal. 2011;55:1111-1119.
65. Qiu X, Bi YA, Balogh LM, Lai Y. Absolute measurement of species differences in sodium taurocholate cotransporting polypeptide (NTCP/Ntcp) and its modulation in cultured hepatocytes. J Pharm Sci. 2013;102:3252-3263.
66. Leslie EM, Watkins PB, Kim RB, Brouwer KL. Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther. 2007;321:1170-1178.
67. Jung D, Hagenbuch B, Fried M, Meier PJ, Kullak-Ublick GA. Role of liver-enriched transcription factors and nuclear receptors in regulating the human, mouse, and rat NTCP gene. Am J Physiol Gastrointest Liver Physiol. 2004;286:G752-G761.
68. Pfeifer ND, Hardwick RN, Brouwer KL. Role of hepatic efflux transporters in regulating systemic and hepatocyte exposure to xenobiotics. Annu Rev Pharmacol Toxicol. 2014;54:509-535.
69. Jemnitz K, Veres Z, Vereczkey L. Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human. Toxicol Sci. 2010;115:80-88.
70. Zelcer N, van de Wetering K, de Waart R, et al. Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol. 2006;44:768-775.
71. Qiu L, Finley J, Taimi M, et al. High-content imaging in human and rat hepatocytes using the fluorescent dyes CLF and CMFDA is not specific enough to assess BSEP/Bsep and/or MRP2/Mrp2 inhibition by cholestatic drugs. Applied In Vitro Toxicology. 2015;1:198-212.
72. Clayton PT. Disorders of bile acid synthesis. J Inherit Metab Dis. 2011;34:593-604.
73. Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis. 2009;4:1.
74. Strautnieks SS, Bull LN, Knisely AS, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet. 1998;20:233-238.
75. Gomez-Ospina N, Potter CJ, Xiao R, et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat Commun. 2016;7:10713.
76. Carlton VE, Harris BZ, Puffenberger EG, et al. Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat Genet. 2003;34:91-96.
77. Wang K. Molecular mechanisms of hepatic apoptosis. Cell Death Dis. 2014;5:e996.
78. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths?. Hepatology. 2006;43:S31-S44.
79. Higuchi H, Bronk SF, Takikawa Y, et al. The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. J Biol Chem. 2001;276:38610-38618.
80. Faubion WA, Guicciardi ME, Miyoshi H, et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Investig. 1999;103:137-145.
81. Gäbele E, Froh M, Arteel GE, et al. TNFα is required for cholestasis-induced liver fibrosis in the mouse. Biochem Biophys Res Comm. 2009;378:348-353.
82. Guicciardi ME, Deussing J, Miyoshi H, et al. Cathepsin B contributes to TNF-α–mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Investig. 2000;106:1127-1137.
83. Werneburg NW, Guicciardi ME, Bronk SF, Kaufmann SH, Gores GJ. Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. J Biol Chem. 2007;282:28960-28970.
84. Bernstein H, Payne CM, Bernstein C, Schneider J, Beard SE, Crowley CL. Activation of the promoters of genes associated with DNA damage, oxidative stress, ER stress and protein malfolding by the bile salt, deoxycholate. Toxicol Lett. 1999;108:37-46.
85. Tamaki N, Hatano E, Taura K, et al. CHOP deficiency attenuates cholestasis-induced liver fibrosis by reduction of hepatocyte injury. Am J Physiol Gastrointest Liver Physiol. 2008;294:G498-G505.
86. Rolo AP, Oliveira PJ, Moreno AJ, Palmeira CM. Bile acids affect liver mitochondrial bioenergetics: possible relevance for cholestasis therapy. Toxicol Sci. 2000;57:177-185.
87. Sokol RJ, Dahl R, Devereaux MW, Yerushalmi B, Kobak GE, Gumpricht E. Human hepatic mitochondria generate reactive oxygen species and undergo the permeability transition in response to hydrophobic bile acids. J Pediatr Gastroenterol Nutr. 2005;41:235-243.
88. Cai S-Y, Ouyang X, Chen Y, et al. Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. JCI insight. 2017;2:e90780.
89. Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol. 2011;178:175-186.
90. Woolbright BL, Antoine DJ, Jenkins RE, Bajt ML, Park BK, Jaeschke H. Plasma biomarkers of liver injury and inflammation demonstrate a lack of apoptosis during obstructive cholestasis in mice. Toxicol Appl Pharmacol. 2013;273:524-531.
91. Woolbright BL, Jaeschke H. Sterile inflammation in acute liver injury: myth or mystery? Expert Rev Gastroenterol Hepatol. 2015;9:1027-1029.
92. Woolbright BL, Dorko K, Antoine DJ, et al. Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis. Toxicol Appl Pharmacol. 2015;283:168-177.
93. Trottier J, Białek A, Caron P, Straka RJ, Milkiewicz P, Barbier O. Profiling circulating and urinary bile acids in patients with biliary obstruction before and after biliary stenting. PLoS ONE. 2011;6:e22094.
94. Grundy S, Lan S-P, Lachin J. The effects of chenodiol on biliary lipids and their association with gallstone dissolution in the National Cooperative Gallstone Study (NCGS). J Clin Invest. 1984;73:1156.
95. Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med. 1994;330:1342-1347.
96. Morrissey K, McSherry C, Swarm R, Nieman W, Deitrick J. Toxicity of chenodeoxycholic acid in the nonhuman primate. Surgery. 1975;77:851.
97. Setchell K, Rodrigues C, Clerici C, et al. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology. 1997;112:226-235.
98. Sturman J, Messing J, Rossi S, Hofmann A, Neuringer M. Tissue taurine content and conjugated bile acid composition of rhesus monkey infants fed a human infant soy-protein formula with or without taurine supplementation for 3 months. Neurochem Res. 1988;13:311-316.
99. Sakakura H, Suzuki M, Kimura N, Takeda H, Nagata S, Maeda M. Simultaneous determination of bile acids in rat bile and serum by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1993;621:123-131.
100. Alnouti Y, Csanaky IL, Klaassen CD. Quantitative-profiling of bile acids and their conjugates in mouse liver, bile, plasma, and urine using LC–MS/MS. J Chromatogr B. 2008;873:209-217.
101. Taylor W. The bile acid composition of rabbit and cat gall-bladder bile. J Steroid Biochem. 1977;8:1077-1084.
102. Mott GE, Jackson EM, McMahan CA. Effects of dietary cholesterol, type of fat, and sex on bile lipid composition of adult baboons. Am J Clin Nutr. 1992;56:511-516.
103. Trautwein EA, Rieckhoff D, Erbersdobler HF. Dietary inulin lowers plasma cholesterol and triacylglycerol and alters biliary bile acid profile in hamsters. J Nutr. 1998;128:1937-1943.
104. Pullinger CR, Eng C, Salen G, et al. Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Investig. 2002;110:109-117.
105. Cheng JB, Jacquemin E, Gerhardt M, et al. Molecular genetics of 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease. J Clin Endocrinol Metab. 2003;88:1833-1841.
106. Lemonde H, Custard E, Bouquet J, et al. Mutations in SRD5B1 (AKR1D1), the gene encoding Δ4-3-oxosteroid 5β-reductase, in hepatitis and liver failure in infancy. Gut. 2003;52:1494-1499.
107. Clayton P, Verrips A, Sistermans E, Mann A, Mieli-Vergani G, Wevers R. Mutations in the sterol 27-hydoxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2002;25:501-513.
108. Setchell KD, Heubi JE, Bove KE, et al. Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy. Gastroenterology. 2003;124:217-232.
109. Monte MJ, Alonso-Peña M, Briz O, et al. ACOX2 deficiency: an inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia. J Hepatol. 2016;66:581-588.
110. Setchell K, Schwarz M, O'Connell NC, et al. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease. J Clin Invest. 1998;102:1690.
111. Ferdinandusse S, Jimenez-Sanchez G, Koster J, et al. A novel bile acid biosynthesis defect due to a deficiency of peroxisomal ABCD3. Hum Mol Genet. 2014;24:361-370.
112. Paulusma CC, Kool M, Bosma PJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology. 1997;25:1539-1542.
113. Sambrotta M, Strautnieks S, Papouli E, et al. Mutations in TJP2 cause progressive cholestatic liver disease. Nat Genet. 2014;46:326-328.
114. Vaz FM, Paulusma CC, Huidekoper H, et al. Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology. 2015;61:260-267.
115. Oelkers P, Kirby LC, Heubi JE, Dawson PA. Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J Clin Investig. 1997;99:1880-1887.
116. Sultan M, Rao A, Elpeleg O, et al. Organic solute transporter-beta (SLC51B) deficiency in two brothers with congenital diarrhea and features of cholestasis. Hepatology. 2017; https://doi.org/10.1002/hep.29516.